Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer

被引：0
|
作者：
Backes, Floor [1 ]
Wei, Lai [1 ]
Copeland, Larry [1 ]
Cohn, David [1 ]
Fowler, Jeffrey [1 ]
Bixel, Kristin [1 ]
Cosgrove, Casey [1 ]
Hays, John [1 ]
Myers, Molly [1 ]
Dodd, Kelly [1 ]
O'Malley, David [1 ]
机构：
[1] Ohio State Univ, Columbus, OH 43210 USA
来源：
GYNECOLOGIC ONCOLOGY | 2021年 / 162卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
120
引用
收藏
页码：S68 / S69
页数：2
相关论文
共 50 条
  • [31] Phase II study of pembrolizumab (pembro) combined with pegylated liposomal doxorubicin (PLD) for recurrent platinum-resistant ovarian, fallopian tube or peritoneal cancer
    Matulonis, U. A.
    Barry, W.
    Penson, R. T.
    Konstantinopoulos, P. A.
    Luo, W.
    Hoffman, M. A.
    Horowitz, N. S.
    Farooq, S.
    Dizon, D. S.
    Stover, E.
    Wright, A. A.
    Campos, S. M.
    Krasner, C.
    Liu, J. F.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 24 - 24
  • [32] PHASE I/II STUDY OF CARBOPLATIN AND PRALATREXATE IN PATIENTS WITH RECURRENT PLATINUM SENSITIVE OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER
    del Carmen, M.
    Campos, S.
    Krasner, C.
    Berlin, S.
    Supko, J.
    Atkinson, T.
    Birrer, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 419 - 420
  • [33] A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer
    Berkenblit, A
    Seiden, MV
    Matulonis, UA
    Penson, RT
    Krasner, CN
    Roche, M
    Mezzetti, L
    Atkinson, T
    Cannistra, SA
    GYNECOLOGIC ONCOLOGY, 2004, 95 (03) : 624 - 631
  • [34] Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
    Liao, John B.
    Gwin, William R.
    Urban, Renata R.
    Hitchcock-Bernhardt, Katie M.
    Coveler, Andrew L.
    Higgins, Doreen M.
    Childs, Jennifer S.
    Shakalia, Hania N.
    Swensen, Ron E.
    Stanton, Sasha E.
    Tinker, Anna, V
    Wahl, Tanya A.
    Ancheta, Richard G.
    McGonigle, Kathryn F.
    Dai, James Y.
    Disis, Mary L.
    Goff, Barbara A.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (09)
  • [35] Phase I study of combination chemotherapy with irinotecan and gemcitabine for taxane/platinum resistant ovarian, fallopian tube, or primary peritoneal cancer
    Yoshino, Kiyoshi
    Kamiura, Shoji
    Ogawa, Haruki
    Tokuhira, Atsushi
    Takemura, Masahiko
    Sawada, Kenjiro
    Ueda, Yutaka
    Mabuchi, Seiji
    Fujita, Masami
    Tsutsui, Tateki
    Kimura, Tadashi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] Outcome of Single Agent Generic Gemcitabine in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Adenocarcinoma
    Suprasert, Prapaporn
    Cheewakriangkrai, Chalong
    Manopunya, Manatsawee
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (02) : 517 - 520
  • [37] Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer
    Backes, Floor J.
    Wei, Lai
    Chen, Min
    Hill, Kasey
    Dzwigalski, Kyle
    Poi, Ming
    Phelps, Mitch
    Salani, Ritu
    Copeland, Larry J.
    Fowler, Jeffrey M.
    Cohn, David E.
    Bixel, Kristin
    Cosgrove, Casey
    Hays, John
    O'Malley, David
    GYNECOLOGIC ONCOLOGY, 2021, 162 (03) : 619 - 625
  • [38] Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal cancer
    Backes, F. J.
    Wei, L.
    Cohn, D. E.
    Salani, R.
    Hays, J. L.
    Fowler, J. M.
    Copeland, L. J.
    O'Malley, D. M.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 23 - 23
  • [39] GLORIOSA: A randomized, open-label, phase 3 study of mirvetuximab soravtansine with bevacizumab vs. bevacizumab as maintenance in platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
    O'Malley, David M.
    Myers, Tashanna K. N.
    Zamagni, Claudio
    Diver, Elisabeth
    Lorusso, Domenica
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer
    Dilawari, Asma
    Shah, Mirat
    Ison, Gwynn
    Gittleman, Haley
    Fiero, Mallorie H.
    Shah, Ankit
    Hamed, Salaheldin S.
    Qiu, Junshan
    Yu, Jingyu
    Manheng, Wimolnut
    Ricks, Tiffany K.
    Pragani, Rajan
    Arudchandran, Arulvathani
    Patel, Paresma
    Zaman, Shadia
    Roy, Arpita
    Kalavar, Shyam
    Ghosh, Soma
    Pierce, William F.
    Rahman, Nam Atiqur
    Tang, Shenghui
    Mixter, Bronwyn D.
    Kluetz, Paul G.
    Pazdur, Richard
    Amiri-Kordestani, Laleh
    CLINICAL CANCER RESEARCH, 2023, 29 (19) : 3835 - 3840
12345